			Declaration of Interests Register						
Technology Appraisal Committee A P					Publi	Publication Date: 07/08/2019			
Topic: Cemiplimab for treating cutaneous squamous cell carcinoma [ID1367]									
Role with NICE	Type of interest	Description of interest	Relevant dates			Comments			
			Interest arose	Interest declared	Interest ceased				
TAC (A) Committee Member	Indirect	Employer, Merck Sharp and Dohme make a similar product to Cemiplimab, PD1. No license pending for this indication	2017	09/04/2019	Ongoing	Declare and participate Chair: Jane Adam Associate Director: Janet Robertson			
TAC (A) Committee Member	Indirect	Attended European Medicines Agency Scientific Advice Procedures panel as a European Patient Expert as a lay panellist for Cemiplimab	August 2018	09/04/2019	March 2019	Declare and Participate Chair: Jane Adam Associate Director: Janet Robertson Programme Director: Helen Knight			
	Ab for treating cut Role with NICE TAC (A) Committee Member TAC (A) Committee	Tab for treating cutaneous squamou Role with NICE Type of interest TAC (A) Indirect Committee Member TAC (A) Indirect TAC (A) Indirect TAC (A) Indirect TAC (A) Indirect	Tab for treating cutaneous squamous cell carcinoma [ID1367] Role with NICE Type of interest Description of interest TAC (A) Indirect Employer, Merck Sharp and Dohme make a similar product to Cemiplimab, PD1. No license pending for this indication TAC (A) Indirect Employer, Merck Sharp and Dohme make a similar product to Cemiplimab, PD1. No license pending for this indication TAC (A) Indirect Attended European Medicines Agency Scientific Advice Procedures panel as a European Patient Expert as a	Ab for treating cutaneous squamous cell carcinoma [ID1367]Role with NICEType of interestDescription of interestRInterest aroseInterest aroseInterest aroseTAC (A) Committee MemberIndirectEmployer, Merck Sharp and Dohme make a similar product to Cemiplimab, PD1. No license pending for this indication2017TAC (A) Committee MemberIndirectAttended European Medicines Agency Scientific Advice Procedures panel as a European Patient Expert as aAugust 2018	Treating cutaneous squamous cell carcinoma [ID1367] Role with NICE Type of interest Description of interest Relevant dates Interest Interest Interest Interest TAC (A) Indirect Employer, Merck Sharp and Dohme make a similar product to Cemiplimab, PD1. No license pending for this indication 2017 09/04/2019 TAC (A) Indirect Attended European Medicines Agency Scientific Advice Procedures panel as a European Patient Expert as a August 2018 09/04/2019	Ab for treating cutaneous squamous cell carcinoma [ID1367] Role with NICE Type of interest Description of interest Relevant dates Interest arose Interest declared Interest ceased TAC (A) Indirect Employer, Merck Sharp and Dohme make a similar product to Cemiplimab, PD1. No license pending for this indication 2017 09/04/2019 Ongoing TAC (A) Indirect Attended European Medicines Agency Scientific Advice Procedures panel as a European Patient Expert as a August 2018 09/04/2019 March 2019			

